Parametrica Management Ltd purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,300 shares of the biopharmaceutical company's stock, valued at approximately $1,367,000. Regeneron Pharmaceuticals accounts for approximately 1.6% of Parametrica Management Ltd's investment portfolio, making the stock its 17th largest position.
Other institutional investors have also recently added to or reduced their stakes in the company. Rakuten Securities Inc. grew its stake in shares of Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 19 shares in the last quarter. Stephens Consulting LLC bought a new position in shares of Regeneron Pharmaceuticals during the second quarter worth about $26,000. Sachetta LLC lifted its position in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 10 shares during the last quarter. Crewe Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals during the first quarter worth about $28,000. Finally, Lynx Investment Advisory bought a new position in shares of Regeneron Pharmaceuticals during the second quarter worth about $33,000. 83.31% of the stock is owned by hedge funds and other institutional investors.
Regeneron Pharmaceuticals Trading Down 2.0 %
Regeneron Pharmaceuticals stock traded down $16.67 during midday trading on Wednesday, reaching $804.33. The stock had a trading volume of 589,526 shares, compared to its average volume of 524,091. The firm's fifty day simple moving average is $1,007.57 and its two-hundred day simple moving average is $1,037.30. Regeneron Pharmaceuticals, Inc. has a twelve month low of $784.96 and a twelve month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The firm has a market cap of $88.39 billion, a price-to-earnings ratio of 19.90, a PEG ratio of 3.10 and a beta of 0.15.
Insider Buying and Selling
In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares of the company's stock, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 7.48% of the company's stock.
Wall Street Analysts Forecast Growth
REGN has been the topic of several research analyst reports. JPMorgan Chase & Co. reduced their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating on the stock in a research report on Thursday, October 24th. Truist Financial reduced their price target on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. Guggenheim raised their target price on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a "buy" rating in a report on Friday, August 2nd. Barclays cut their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating on the stock in a report on Friday, November 1st. Finally, Morgan Stanley cut their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating on the stock in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $1,107.25.
Check Out Our Latest Research Report on Regeneron Pharmaceuticals
About Regeneron Pharmaceuticals
(
Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Further Reading
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
